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Figure 1. Comparison of total number of SNP (WES) in each DRP, in silico derived nona-peptides with strong binding (IC50 <50 nm) and strong-week binding (IC50
<500 nM).
Figure 2. IC50 values of peptide-HLA complexes for MRD (red) URD (blue) for
IC50 < 500nm. Data for a single allele presented. Peptides below the black line
are strong binding (IC50 <50 nm).
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1.2% of all the above peptides were categorized as presented
by the HLA class I molecules in the DRP examined, with a
smaller fraction of these peptides being strong binders (IC50
<50nM). (Fig 1) In our small cohort, MRD presented a me-
dian 3% (range 1-10) of all the predicted peptides, compared
with 13.5% (4-20) for the URD. Further, plotting the IC50
values of the presented-peptides in each DRP, demonstrated
a continuum of binding afﬁnities (Fig 2) as opposed to
discrete sets of values taken on by different peptides,
implying a certain degree of plasticity in this system.
Computing the area under the curve for these data to account
for both number of and binding afﬁnity of peptide-HLA
complexes, demonstrated amarked difference betweenMRD
(1x10
ˇ
6 nM.Peptide-HLA) and URD (8x10
ˇ
6). Our data dem-
onstrates that a marked difference is evident between URD
and MRD when WES is used to predict potential protein-
coding differences - estimating an HLA-speciﬁc AP in unique
DRP. This represents a paradigm shift away from looking for
unique mHA to predict likelihood of developing GVH phe-
nomenon in a population-basedmanner, andmay eventually
better deﬁne GVHD risk in HLA matched DRP.420
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Graft versus host disease (GvHD) is an often fatal complica-
tion of allogeneic tissue transplantation. While typical tar-
gets of GvHD include the skin, lung, liver and GI tract, a
myriad of other organ systems are being identiﬁed as targets
of this disease. Although the neurologic complications that
occur during hematopoietic stem cell transplant (HCT) have
been extensively described (Siegal et al., BBMT, 2007), little
information is available about the incidence and biology of
GvHD in the central nervous system (CNS). Case reports have
shown that the CNS can be a target of GvHD and show high
mortality rates when involved (Saad et al., JCO, 2009). A
recent study found both pathologic and behavioral conse-
quences of CNS-GVHD in a mouse model (Hartrampf et al.,
Blood, 2013). Further study of CNS-GvHD is needed to better
understand this entity that is often difﬁcult to access
clinically.
Non-human primates have been shown to closely model
humans during and after HCT. To investigate the prevalence
of CNS manifestations of acute GvHD such a model, we
conducted a HCT study with the following Transplant/GvHD
prophylaxis regimens: 1) Autologous/None 2) Allogeneic/
Figure 1. Meningeal inﬂammation of rhesus monkeys during acute GvHD is characterized by an inﬁltration of activated CD8+ lymphocytes that does not occur during
GvHD prophylactic therapy.
(A) Immunohistochemical stains for speciﬁc antibodies within the CNS meninges of animals undergoing various HSCT regimens and GvHD prophylactic regimens are
shown. (B) Number of cells per 10X ﬁeld were quantiﬁed and scored from 0 to 11 based on the number of positive cells (0¼ no cells; 1 ¼1-5 cells; 2 ¼ 6-10 cells; 3 ¼
11 - 15 cells; 4 ¼ 16-20 cells; 5 ¼ 21-25 cells; 6 ¼ 26-30 cells; 7 ¼ 31-35 cells; 8 ¼ 36-40 cells; 9 ¼ 41-45 cells; 10 ¼ 46-50 cells, 11 ¼ > 51 cells.). The p-values as
calculated by Mann-Whitney test are represented above the respective bars;* indicates statistical signiﬁcance (P <0.05).
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neic/Rapamycin. Immunohistochemistry performed on the
CNSmeninges of untreated HCT recipients with severe GvHD
demonstrated a CD3+, CD20- meningeal lymphocytic inﬁl-
tration, which was not observed in autologous transplants
(Figure 1) and which was accompanied by signiﬁcant
behavioral abnormalities and neurologic compromise. TheFigure 2. LFA-1 is highly expressed on activated CD8+ lymphocytes inﬁltrating CNS d
stains for LFA-1 within the CNS menings of normal control and allogenic-HCT-no treat
0 to 11 based on the number of positive cells (0¼ no cells; 1¼1-5 cells; 2 ¼ 6-10 cells;
8 ¼ 36-40 cells; 9 ¼ 41-45 cells; 10 ¼ 46-50 cells; 11¼ > 51 cells.). The p-value as calcu
signiﬁcance (P < 0.05).number of CD8+ cells found in these inﬁltrates was signiﬁ-
cantly higher in animals with GvHD than in either controls or
in animals treated with Tac/Mtx or Rapamycin prophylaxis.
CNS-inﬁltrating cells demonstrated higher expression of
granzyme B (Figure 1) and Ki-67 (not shown), which is
consistent with previous characterization of the CD8+ func-
tional status during acute GvHD in a non-human primateuring acute GvHD in a non-human primate model. (A) Immunohistochemical
ment animals B) Number of cells per 10X ﬁeld were quantiﬁed and scored form
3 ¼ 11-15 cells; 4¼ 16-20 cells; 5 ¼ 21-25 cells; 6 ¼ 26-30 cells; 7¼ 31-35 cells;
lated by Mann-Whitney test is represented above the bar;* indicated statistical
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show that LFA-1 expression is highly upregulated in CNS
leukocyte inﬁltrates of animals with untreated GvHD (Figure
2). LFA-1 is an integrin that is critical for leukocyte trafﬁcking
into the CNS during demyelinating disease (Hu et al., J Leuk
Bio, 2010). These results suggest that the mechanisms of T
cell inﬁltration into the CNS during GVHD may have impor-
tant similarities to autoimmune-mediated CNS diseases such
as multiple sclerosis, and thus may be amenable to targeted
therapies such as integrin-blockade.
Our ﬁndings argue that CNS-GvHD can occur in primates
undergoing HCT, and is characterized by an inﬁltrate of
activated, integrin-expressing CD8 T cells. These results un-
derscore the importance of including GVHD in the differen-
tial diagnosis of CNS symptoms after HCT, and suggest that
targeted therapeutic strategies may be able to address this
often under-recognized complication of HCT.
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In the developed world, vitamin C deﬁciency is typically only
seen in patients with diseases that result in signiﬁcantly
impaired oral intake, including cystic ﬁbrosis and anorexia
nervosa, or in patients requiring long-term enteral tube
feeding. Patients with chronic graft versus host disease
(GVHD) with mucosal involvement should also be assessed
for this deﬁciency, as intake of acidic foods rich in vitamin C
is often reduced as a result of pain with ingestion. We report
here a clinical observation of vitamin C deﬁciency (levels
ranging from<0.12 to 0.94mg/dL, median level 0.6mg/dL) in
6 pediatric and adolescent patients with a median age of 17.5
years (range 9.8-23.5). In these patients, mucositis, as evi-
denced by signs and symptoms such mucoceles, leukoplakia,
cheilosis, chelitis, and bleeding associated with tooth
brushing, did not improve with conventional therapies for
chronic GVHD. Mucositis was assessed according to the NIH
criteria. When vitamin C deﬁciency was noted, patients were
started on treatment with ascorbic acid 2000mg by mouthdaily. After 4 and 8 weeks of therapy, patients showed an
increase in mean serum vitamin C concentrations to 1.25 
0.95 mg/dL (median 1.005 mg/dL) and 1.31  0.67 mg/dL
(median 1.33mg/dL), respectively. Subsequently, all patients
demonstratedmarked visual improvement in their mucositis
symptoms and improved oral intake.422
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Background: Involvement of joints and fascia by chronic
GVHD (cGVHD) is a prominent contributor to cGVHD-asso-
ciated disability. NIH cGVHD Joint and Fascia Score (JFS, range
0-3) consists of three measurements: tightness, restriction in
measured range of motion (ROM) and limitations in activities
of daily living (ADL). The NIH consensus criteria did not
distinguish the contributions to JFS made by isolated joint
involvement vs. joint restrictions caused by sclerosis of
overlying skin, as well as most studies fail to distinguish it.
The purpose of this study was to compare patients with
isolated joint-fascia (JF) involvement to JF involvement with
overlying skin and soft tissue sclerosis, and to identify pre-
dictive factors for isolated joint involvement in a cohort of
cGVHD patients.
Patients and Methods: In a cross-sectional cGVHD natural
history study (n¼283, median age 43 years, range 4-70), 169
(60%) had JF involvement at the time of enrollment; mild
(n¼60), moderate (n¼78), severe (n¼31). Only 27 (16%) pa-
tients with JFS involvement had no (n¼11) or mild (n¼16)
skin score (NIH 0-1). Clinical assessments includedmeasured
active assisted ROM, grip strength, 2 minute walk, Lee
cGVHD symptom scale, Human Activity Proﬁle (HAP) and
selected laboratory parameters. JFS-positive patients (NIH
JFS score 1-3) with joint restrictions and no sclerotic skin
changes (n¼43) were compared to JFS-positive sclerotic
cGVHD (n¼126).
Results: JFS-positive patients (n¼169) had signiﬁcantly more
skin erythema, dermal and deep sclerosis. Only 27 (16%) of
JFS-positive patients had NIH skin scores of 0 (n¼11) or 1
(n¼16). JFS-positive patients without evidence of sclerotic
cGVHD had signiﬁcantly shorter duration of cGVHD (p<.001)
and were considered to have more active cGVHD based on
therapeutic intent (p<.0001), but had lower NIH global
